Q-omics provides the consensus-scored PLCD4 profile across patient tissues and cancer cell-line models. PLCD4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PLCD4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PLCD4 RNA expression shows 21,168 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where PLCD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLCD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLCD4 survival associations across molecular data types. PLCD4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLCD4 RNA expression–survival associations across cancer types. High PLCD4 expression shows unfavorable associations in ACC, UVM, UCEC, LUAD and LIHC, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PLCD4 RNA expression.
This table summarizes PLCD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLCD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLCD4 shows lower tumor expression in KIRC, BLCA, THCA, COAD and KIRP and higher tumor expression in LIHC. The KIRC box plot shows higher PLCD4 RNA expression in normal versus tumor tissue (log2 FC = −0.769, t-test p < 0.001).
This table shows molecular features associated with PLCD4 in patient tissues and cancer cell lines. In patient samples, PLCD4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLCD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
